(RCKT) Rocket Pharmaceuticals - Overview
Stock: AAV Gene Therapies, LV Gene Therapies, Rare Diseases
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 85.7% |
| Relative Tail Risk | -15.9% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.50 |
| Alpha | -90.36 |
| Character TTM | |
|---|---|
| Beta | 1.245 |
| Beta Downside | 1.995 |
| Drawdowns 3y | |
|---|---|
| Max DD | 92.71% |
| CAGR/Max DD | -0.50 |
Description: RCKT Rocket Pharmaceuticals January 01, 2026
Rocket Pharmaceuticals (NASDAQ:RCKT) is a late-stage biotech focused on AAV-based gene therapies for rare, life-threatening diseases in the United States. Its lead AAV candidates include RP-A501 for Danon disease (Phase 2), RP-A601 for PKP2-arrhythmogenic cardiomyopathy (Phase 1) and a pre-clinical BAG3-dilated cardiomyopathy program. The company also pursues lentiviral (LV) approaches targeting Leukocyte Adhesion Deficiency-I (RP-L201), Fanconi Anemia (RP-L102) and Pyruvate Kinase Deficiency (RP-L301), each supported by multiple university and corporate licensing agreements.
Key operational metrics (as of the most recent 10-Q, May 2024) show a cash position of roughly $180 million, giving an estimated runway of 12-18 months at current burn rates. RCKT’s market-cap sits near $350 million, reflecting a price-to-cash ratio of ~2×, which is modest relative to the broader gene-therapy sector where average forward-price-to-sales multiples hover around 12×. The AAV market is projected to grow at a CAGR of ~13 % through 2030, driven by expanding FDA approvals and payer acceptance for rare-disease treatments-factors that could materially uplift RCKT’s valuation if its Phase 2 Danon disease trial meets primary endpoints.
For a deeper quantitative assessment, consider reviewing the detailed financial and pipeline analytics available on the ValueRay platform.
Piotroski VR‑10 (Strict, 0-10) 1.0
| Net Income: -240.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.55 > 0.02 and ΔFCF/TA -3.70 > 1.0 |
| NWC/Revenue: 2139 % < 20% (prev 1957 %; Δ 182.5% < -1%) |
| CFO/TA -0.55 > 3% & CFO -202.2m > Net Income -240.9m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 7.30 > 1.5 & < 3 |
| Outstanding Shares: last quarter (111.6m) vs 12m ago 18.49% < -2% |
| Gross Margin: 39.82% > 18% (prev -0.18%; Δ 4000 % > 0.5%) |
| Asset Turnover: 2.41% > 50% (prev 2.62%; Δ -0.21% > 0%) |
| Interest Coverage Ratio: -126.4 > 6 (EBITDA TTM -227.9m / Interest Expense TTM 1.89m) |
Altman Z'' -15.00
| A: 0.53 (Total Current Assets 227.7m - Total Current Liabilities 31.2m) / Total Assets 368.0m |
| B: -3.80 (Retained Earnings -1.40b / Total Assets 368.0m) |
| C: -0.63 (EBIT TTM -239.0m / Avg Total Assets 380.9m) |
| D: -25.71 (Book Value of Equity -1.40b / Total Liabilities 54.4m) |
| Altman-Z'' Score: -40.10 = D |
What is the price of RCKT shares?
Over the past week, the price has changed by -9.20%, over one month by -10.73%, over three months by -2.17% and over the past year by -70.33%.
Is RCKT a buy, sell or hold?
- StrongBuy: 12
- Buy: 5
- Hold: 1
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the RCKT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 7.7 | 142.1% |
| Analysts Target Price | 7.7 | 142.1% |
| ValueRay Target Price | 2.2 | -30.4% |
RCKT Fundamental Data Overview February 03, 2026
Revenue TTM = 9.19m USD
EBIT TTM = -239.0m USD
EBITDA TTM = -227.9m USD
Long Term Debt = 25.0m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 2.91m USD (from shortTermDebt, last quarter)
Debt = 25.0m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -50.9m USD (from netDebt column, last quarter)
Enterprise Value = 178.9m USD (376.6m + Debt 25.0m - CCE 222.8m)
Interest Coverage Ratio = -126.4 (Ebit TTM -239.0m / Interest Expense TTM 1.89m)
EV/FCF = -0.88x (Enterprise Value 178.9m / FCF TTM -202.8m)
FCF Yield = -113.4% (FCF TTM -202.8m / Enterprise Value 178.9m)
FCF Margin = -2208 % (FCF TTM -202.8m / Revenue TTM 9.19m)
Net Margin = -2623 % (Net Income TTM -240.9m / Revenue TTM 9.19m)
Gross Margin = 39.82% ((Revenue TTM 9.19m - Cost of Revenue TTM 5.53m) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 0.49 (Enterprise Value 178.9m / Total Assets 368.0m)
Interest Expense / Debt = 1.89% (Interest Expense 473.0k / Debt 25.0m)
Taxrate = 21.0% (US default 21%)
NOPAT = -188.8m (EBIT -239.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 7.30 (Total Current Assets 227.7m / Total Current Liabilities 31.2m)
Debt / Equity = 0.08 (Debt 25.0m / totalStockholderEquity, last quarter 313.7m)
Debt / EBITDA = 0.22 (negative EBITDA) (Net Debt -50.9m / EBITDA -227.9m)
Debt / FCF = 0.25 (negative FCF - burning cash) (Net Debt -50.9m / FCF TTM -202.8m)
Total Stockholder Equity = 385.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -63.25% (Net Income -240.9m / Total Assets 368.0m)
RoE = -62.44% (Net Income TTM -240.9m / Total Stockholder Equity 385.8m)
RoCE = -58.18% (EBIT -239.0m / Capital Employed (Equity 385.8m + L.T.Debt 25.0m))
RoIC = -48.94% (negative operating profit) (NOPAT -188.8m / Invested Capital 385.8m)
WACC = 9.94% (E(376.6m)/V(401.7m) * Re(10.50%) + D(25.0m)/V(401.7m) * Rd(1.89%) * (1-Tc(0.21)))
Discount Rate = 10.50% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 15.24%
Fair Price DCF = unknown (Cash Flow -202.8m)
EPS Correlation: 71.43 | EPS CAGR: 35.22% | SUE: 4.0 | # QB: 1
Revenue Correlation: 20.18 | Revenue CAGR: 0.0% | SUE: -0.17 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.44 | Chg30d=+0.000 | Revisions Net=+1 | Analysts=7
EPS next Year (2026-12-31): EPS=-1.25 | Chg30d=+0.048 | Revisions Net=-3 | Growth EPS=+38.3% | Growth Revenue=+0.0%